(S)-2-(Butylsulfonamido)-3-(4-(4-(piperidin-4-yl)butoxy)phenyl)propanoicacidhydrochloride , 97% , 142373-60-2
CAS NO.：142373-60-2
Empirical Formula: C22H39ClN2O6S
Molecular Weight: 495.07
MDL number: MFCD00868210
| Pack Size | Price | Stock | Quantity |
| 1g | RMB1663.20 | In Stock |
|
| others | Enquire |
PRODUCT Properties
| Melting point: | 83-87oC |
| solubility | Methanol (Slightly) |
| form | Solid |
| color | White |
| InChIKey | HWAAPJPFZPHHBC-MGIYCFTINA-N |
| SMILES | S(CCCC)(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC1CCNCC1)C(O)=O.Cl.O |&1:8,r| |
| CAS DataBase Reference | 142373-60-2 |
Description and Uses
Tirofiban was launched as Aggrastat in Switzerland and the US for patients with unstable angina or non-Q-wave myocardial infarction to prevent cardiac ischemic events. Tirofiban is synthesized from (S)-tyrosine by a fourstep process. Tirofiban is a novel highly potent antiplatelet agent that inhibits the interaction of fibrinogen with GPⅡb/Ⅲa, an activated platelet membrane-bound glycoprotein complex. It prevents arterial thrombus formation in a dosedependent manner. Clinical efficacy was highly significant with an absolute and relative risk reduction. In these studies, treatment with tirofiban was well tolerated, without significant adverse effects.
Tirofiban Hydrochloride is a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist.
Safety
| Symbol(GHS) |  GHS07 |
| Signal word | Warning |
| Hazard statements | H302-H315-H319-H335 |
| Precautionary statements | P261-P305+P351+P338 |
